Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

D7400C00006

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT04594642)

Currently recruiting

D7405C00001

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (NCT06137118)

Currently recruiting

DAPA_HF

Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) (ACTRN12621000187842)

Currently recruiting

Daratumumab@Home

A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (ACTRN12624001468516)

Currently recruiting

DASL-HiCaP

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [ANZUP1801]. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. 
Currently recruiting

DB in asthma

Targeted treatment for people with dysfunctional breathing and difficult asthma (ACTRN12624001285549)

Currently recruiting

DCD-HOPE

Hypothermic Oxygenated Perfusion (HOPE) in Donation after Circulatory Death (DCD) for Heart Transplantation (Registration Pending)

Coming soon

DECIDE

DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (ACTRN12623001171606)

Currently recruiting

DEFINE

The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity (ACTRN12624000270516)

Coming soon

DEFiNE GPS

Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting (short title: DEFiNE GPS) (NCT04451044)

Currently recruiting

DeLLphi-304

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (NCT05740566)

No longer recruiting

DeLLphi-308

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeLLphi-308] (NCT06598306)

Currently recruiting

DeLLphi-308

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeLLphi-308] (NCT06598306)

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Currently recruiting

DepleTTR-CM

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (NCT06183931)

Currently recruiting

Dianthus-CAPTIVATE

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (NCT06858579)

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Currently recruiting

DIRECT Trial

GuiDIng energy provision using indiREct CalorimeTry: a pilot feasibility randomised controlled trial in critically ill adults with obesity [DIRECT Trial] (NCT06053216)

Indirect calorimetry is the gold standard for measuring energy expenditure in critically ill patients, but its impact on outcomes versus predictive equations is unclear. This study assesses the feasibility of using repeated measurements to guide energy delivery in obese ICU patients, with a secondary goal of informing a larger trial.
Currently recruiting

DIRECT/InspIRE Australia

A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN12621000955819)

Currently recruiting

Discovery 530 cardiac camera LVEF study

Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (Trial Not Registered)

Currently recruiting

DISCUS

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)

Currently recruiting

DREAMM-10

A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone [BRd] versus daratumumab, lenalidomide, and dexamethasone [DRd] in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (NCT06679101)

The study will evaluate if belantamab mafodotin, lenalidomide and dexamethasone prolongs progression-free overall survival compared to daratumumab, lenalidomide and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Currently recruiting
9 10 11 12 13